Compare AUBN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | ALXO |
|---|---|---|
| Founded | 1907 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 79.7M |
| IPO Year | 1995 | 2020 |
| Metric | AUBN | ALXO |
|---|---|---|
| Price | $24.85 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 1.6K | ★ 303.0K |
| Earning Date | 10-23-2025 | 11-07-2025 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 754.96 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $32,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | ★ 40.58 | N/A |
| 52 Week Low | $19.00 | $0.40 |
| 52 Week High | $29.00 | $2.27 |
| Indicator | AUBN | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 50.21 |
| Support Level | $24.07 | $1.29 |
| Resistance Level | $25.10 | $1.56 |
| Average True Range (ATR) | 0.57 | 0.14 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 52.81 | 47.83 |
Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.